According to a study by Lancet Regional Health Southeast Asia journal, (LANCET) it has been found that a nasal spray has the ability to reduce COVID-19 viral load within 24 hours. The study also states that such nasal sprays which have been administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours. The said study has been observed regards to the phase 3 trial of the drug published in the LANCET journal.
The Nitric Oxide Nasal Spray (NONS) study was conducted during the Delta and Omicron variant surge, by Mumbai-based pharmaceutical company Glenmark in 306 vaccinated and unvaccinated adults with symptomatic mild COVID-19 across 20 clinical sites in India. The research stated that high-risk patients who received NONS had a significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
However, the trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19. NONS was self-administered six times daily as two sprays per nostril for seven days.
The authors who have drafted the study have confirmed that the viral load was reduced by 93.7 per cent within 24 hours and by 99 per cent within 48 hours of treatment with NONS. Similar results were observed in vaccinated and unvaccinated populations as well.
One of the authors of the study, Monika Tandon, Senior VP & Head – Clinical Development, Glenmark said, “The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in the current highly transmissible phase of the pandemic.”
The Nitric Oxide Nasal Spray (NONS) was launched in India under the brand name FabiSpray in the month of February after it received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the immediate approval process.
Statement from the study also says that using NONS blocks entry into the nasal passage, thus killing the virus, hence a complete stop in its replication, this is the reason why the viral load is reduced so rapidly with NONS. The median time to viral cure was three days in the NONS group and seven days in the placebo group after the start of the treatment, it said.
The authors of the study added saying, that the proportion of immediate contacts having a positive COVID-19 test or becoming symptomatic, remained nearly the same in the NONS group while it numerically increased in the placebo group over the treatment.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
